The Use of Mapping to Estimate Health State Utility Values.

abstract：BACKGROUND:The use of granulocyte colony-stimulating factor (G-CSF) can enable dose intensification of chemotherapy in small-cell lung cancer (SCLC). However, given its acquisition cost, it is important to assess its cost effectiveness within a resource-constrained health service. OBJECTIVE:To assess the cost effectiv...

journal_title：PharmacoEconomics

authors： Bojke L,Sculpher M,Stephens R,Qian W,Thatcher N,Girling D

更新日期：2006-01-01 00:00:00

abstract：OBJECTIVES:Discrete choice experiments (DCEs) are increasingly advocated as a way to quantify preferences for health. However, increasing support does not necessarily result in increasing quality. Although specific reviews have been conducted in certain contexts, there exists no recent description of the general state ...

journal_title：PharmacoEconomics

authors： Soekhai V,de Bekker-Grob EW,Ellis AR,Vass CM

更新日期：2019-02-01 00:00:00

abstract：:The recent multinational, randomised, prospective studies Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE), Percutaneous Coronary Intervention substudy of CURE (PCI-CURE) and Clopidogrel for the Reduction of Events During Observation (CREDO) have demonstrated the clinical efficacy and safety of clopid...

journal_title：PharmacoEconomics

authors： Weintraub W,Jönsson B,Bertrand M

更新日期：2004-01-01 00:00:00

abstract：:As part of its Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer of evolocumab (Amgen) to submit evidence on the clinical and cost effectiveness of evolocumab. The appraisal assessed evolocumab as monotherapy or in combination with a statin...

journal_title：PharmacoEconomics

authors： Carroll C,Tappenden P,Rafia R,Hamilton J,Chambers D,Clowes M,Durrington P,Qureshi N,Wierzbicki AS

更新日期：2016-11-16 00:00:00

abstract：:Disease management is a systematic approach to a health condition or a healthcare intervention that organises preventative, interventional and care approaches throughout the continuum of care and which measures outcomes in terms of populations, not individuals. Disease management's advantage over the current component...

journal_title：PharmacoEconomics

authors： Chang K,Nash D

更新日期：1998-07-01 00:00:00

abstract：INTRODUCTION:This analysis compared the cost effectiveness of adding ezetimibe to atorvastatin therapy versus atorvastatin titration or adding cholestyramine (a resin) for patients at high risk of a coronary artery disease (CAD) event who did not reach target cholesterol levels on their current atorvastatin dosage. The...

journal_title：PharmacoEconomics

authors： Kohli M,Attard C,Lam A,Huse D,Cook J,Bourgault C,Alemao E,Yin D,Marentette M

更新日期：2006-01-01 00:00:00

abstract：:The development of evidence to demonstrate 'value for money' is regarded as an important step in facilitating the search for the optimal allocation of limited resources and has become an essential component in healthcare decision making. Real-world evidence collected from de-identified individuals throughout the conti...

journal_title：PharmacoEconomics

authors： Kolasa K,Ken Redekop W,Berler A,Zah V,Asche CV

更新日期：2020-10-01 00:00:00

abstract：:Health economic models for identifying therapeutic options that maximise health benefits from limited healthcare resources are being developed in a number of therapeutic areas. The development of such a model for upper gastrointestinal (UGI) symptoms to support decision-making by primary care clinicians is of particul...

journal_title：PharmacoEconomics

authors： Haycox A,Butterworth M,Walley T,Barton S

更新日期：1998-01-01 00:00:00

abstract：OBJECTIVE:Economic evaluations of new diabetes therapies rely heavily upon the UK Prospective Diabetes Study (UKPDS) equations for prediction of cardiovascular events; however, concerns persist regarding their relevance to current clinical practice and appropriate use in populations other than newly diagnosed patients....

journal_title：PharmacoEconomics

authors： McEwan P,Bennett H,Ward T,Bergenheim K

更新日期：2015-02-01 00:00:00

abstract：:Deterministic sensitivity analyses (DSA) remain important to interpret the effect of uncertainties in individual parameters on results of cost-effectiveness analyses. Classic DSA methodologies may lead to wrong conclusions due to a lack of or misleading information regarding marginal effects, non-linearity, likelihood...

journal_title：PharmacoEconomics

authors： Vreman RA,Geenen JW,Knies S,Mantel-Teeuwisse AK,Leufkens HGM,Goettsch WG

更新日期：2021-01-01 00:00:00

abstract：:The annual cost of managing migraine totals billions of US dollars. This retrospective economic analysis of a clinical trial comparing subcutaneous dihydroergotamine mesylate (DHE) with subcutaneous sumatriptan in the treatment of acute migraine is appropriate because, although each product has been shown to be effica...

journal_title：PharmacoEconomics

authors： Payne K,Kozma CM,Lawrence BJ

更新日期：1996-07-01 00:00:00

abstract：:The pharmaceutical industry's core business is the innovation, development and marketing of new drugs. Pharmacogenetic (PG) testing and technology has the potential to increase a drug's value in many ways. A critical issue for the industry is whether products in development should be teamed with genetic tests that cou...

journal_title：PharmacoEconomics

authors： Vernon JA,Johnson SJ,Hughen WK,Trujillo A

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND:Pharmaceuticals are usually granted a marketing authorisation on the basis of randomised controlled trials (RCTs). Occasionally the efficacy of a treatment is assessed without a randomised comparator group (either active or placebo). OBJECTIVE:To identify and develop a taxonomic account of economic modellin...

journal_title：PharmacoEconomics

authors： Hatswell AJ,Freemantle N,Baio G

更新日期：2017-02-01 00:00:00

abstract：BACKGROUND:Several vaccine and antibody candidates are currently in development for the prevention of lower respiratory tract infections caused by the respiratory syncytial virus (RSV). METHODS:We searched MEDLINE, Embase, and SCOPUS and included model-based evaluations of RSV vaccinations. Two reviewers performed the...

journal_title：PharmacoEconomics

authors： Treskova M,Pozo-Martin F,Scholz S,Schönfeld V,Wichmann O,Harder T

更新日期：2021-01-19 00:00:00

abstract：:This article examines the twin concepts of the statistical significance and quantitative importance of observed differences in studies comparing medicines in terms of economic parameters such as cost-effectiveness and measures of health-related quality of life (HRQOL). Central to the design and interpretation of any ...

journal_title：PharmacoEconomics

authors： O'Brien BJ,Drummond MF

更新日期：1994-05-01 00:00:00

abstract：:As part of the National Institute for Health and Care Excellence's (NICE) Single Technology Appraisal (STA) process, ruxolitinib was assessed to determine the clinical and cost effectiveness of its use in the treatment of disease-related splenomegaly or symptoms in adults with myelofibrosis. Ruxolitinib had previously...

journal_title：PharmacoEconomics

authors： Wade R,Hodgson R,Biswas M,Harden M,Woolacott N

更新日期：2017-02-01 00:00:00

abstract：:Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders, with an estimated prevalence rate in the general population of 10-15% in industrialised countries. Although IBS is not a life-threatening disease, it contributes significantly to a large segment of healthcare resource consu...

journal_title：PharmacoEconomics

authors： Maxion-Bergemann S,Thielecke F,Abel F,Bergemann R

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND:The symptoms of attention-deficit hyperactivity disorder (ADHD) are associated with impairment in multiple domains of health-related quality of life (HR-QOL). HR-QOL of children with ADHD has been assessed by relatively long multidimensional questionnaires. A review of the literature found no studies using t...

journal_title：PharmacoEconomics

authors： Matza LS,Secnik K,Mannix S,Sallee FR

更新日期：2005-01-01 00:00:00

abstract：OBJECTIVE:The aim of this review is to provide a summary of the literature on risk-sharing agreements, including conceptual, theoretical and empirical (number of agreements and their achievements) perspectives, and stakeholders'  perceptions. METHODS:We conducted a systematic literature search in MEDLINE from 2000 to ...

journal_title：PharmacoEconomics

authors： Antonanzas F,Juárez-Castelló C,Lorente R,Rodríguez-Ibeas R

更新日期：2019-12-01 00:00:00

abstract：:Health economic modelling studies are of interest to many parties with different responsibilities and diverging interests. Therefore, it is obvious that recognising the relevance of statistical uncertainty and dealing with it appropriately are required to obtain unbiased results from health economic modelling studies,...

journal_title：PharmacoEconomics

authors： Nuijten MJ

更新日期：2004-01-01 00:00:00

abstract：:There are insufficient resources in the UK to fund all new technologies and new indications approved by the National Institute for Health and Clinical Excellence (NICE). Diverting funding from existing sources will have a detrimental effect on the provision of other priority services. The UK Office of Fair Trading (OF...

journal_title：PharmacoEconomics

authors： Godman B,Haycox A,Schwabe U,Joppi R,Garattini S

更新日期：2008-01-01 00:00:00

abstract：OBJECTIVE:To estimate the potential savings in overall cardiovascular disease (CVD) treatment costs for the US population with coronary artery disease (CAD) resulting from the use of amlodipine. STUDY DESIGN AND METHODS:Using patient-level data from a retrospective analysis of the Prospective Evaluation of the Vascula...

journal_title：PharmacoEconomics

authors： Casciano R,Doyle JJ,Chen J,Arikian S,Casciano J,Kugel H,Arocho R

更新日期：2002-01-01 00:00:00

abstract：:Venetoclax is licensed to treat relapsed or refractory (R/R) chronic lymphocytic leukaemia (CLL). As part of the Single Technology Appraisal (STA) ID944, the National Institute for Health and Care Excellence (NICE) invited AbbVie, the manufacturer, to submit evidence on the use of venetoclax, within its licensed indic...

journal_title：PharmacoEconomics

authors： Mistry H,Nduka C,Connock M,Colquitt J,Mantopoulos T,Loveman E,Walewska R,Mason J

更新日期：2018-04-01 00:00:00

abstract：BACKGROUND:Like other developed countries with aging populations, Sweden is expecting large increases in the prevalence of Alzheimer's disease and corresponding escalations in the cost of care for patients with this disease. Galantamine, a new acetylcholinesterase inhibitor and nicotinic modulator, has proved effective...

journal_title：PharmacoEconomics

authors： Garfield FB,Getsios D,Caro JJ,Wimo A,Winblad B

更新日期：2002-01-01 00:00:00

abstract：:The original article can be found online. ...

journal_title：PharmacoEconomics

authors： Paulden M

更新日期：2020-10-01 00:00:00

abstract：:Appropriate discounting rules in economic evaluations have received considerable attention in the literature and in national guidelines for economic evaluations. Rightfully so, as discounting can be quite influential on the outcomes of economic evaluations. The most prominent controversies regarding discounting involv...

journal_title：PharmacoEconomics

authors： Attema AE,Brouwer WBF,Claxton K

更新日期：2018-07-01 00:00:00

abstract：:The role of economic evaluation in the efficient allocation of healthcare resources has been widely debated. Whilst economic evidence is undoubtedly useful to purchasers, it does not address the issue of affordability which is an increasing concern. Healthcare purchasers are concerned not just with maximising efficien...

journal_title：PharmacoEconomics

authors： Trueman P,Drummond M,Hutton J

更新日期：2001-01-01 00:00:00

abstract：:Health economic evaluation is a framework for the comparative analysis of the incremental health gains and costs associated with competing decision alternatives. The process of developing health economic models is usually complex, financially expensive and time-consuming. For these reasons, model development is someti...

journal_title：PharmacoEconomics

authors： Bermejo I,Tappenden P,Youn JH

更新日期：2017-11-01 00:00:00

abstract：:Recombinant human erythropoietin (rHuEpo) has been increasingly used in preterm infants in the last 3 to 4 years. Recent studies have indicated a reduction in blood transfusion requirements in infants receiving rHuEpo. No significant adverse effects have emerged, apart from iron deficiency (if iron supplementation is ...

journal_title：PharmacoEconomics

authors： Meyer MP

更新日期：1997-10-01 00:00:00

abstract：OBJECTIVE:Cost is an issue when prescribing two drugs with equivalent efficacy. We compared the direct medical costs of topical brinzolamide 1% (twice a day or three times daily) with topical dorzolamide 2% (twice a day or three times daily) in France, Italy, Portugal and Spain in patients with ocular hypertension or p...

journal_title：PharmacoEconomics

authors： Rouland JF,Le Pen C,Gouveia Pinto C,Berto P,Berdeaux G

更新日期：2003-01-01 00:00:00